» Articles » PMID: 9607615

The Molecular Pathobiology of Cell Membrane Iron: the Sickle Red Cell As a Model

Overview
Date 1998 Jun 2
PMID 9607615
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

The molecular pathobiology of membrane-associated iron is clearly illustrated by the sickle red blood cell. The cytosolic aspect of the membranes of these cells carries several discrete iron compartments, including denatured hemoglobin and free heme, as well as molecular iron associated with membrane aminophospholipid and denatured globin. Affinity of the membrane for molecular iron is extraordinarily high and predicted to keep cytosolic free iron concentration < 10(-20) M. Membrane iron is bioactive and able to valence cycle, thus serving as a catalyst for generation of highly reactive hydroxyl radical. As a consequence of this oxidative biochemistry at the cytosol/membrane interface, multiple membrane defects arise that are of pathophysiologic importance. Thus, sickle red cells provide a pathobiologic paradigm for the membrane-damaging effect of iron-mediated targeting of oxidative damage at a sub-cellular level. This is relevant to a variety of biologic conditions accompanied by decompartmentalization of iron.

Citing Articles

Impaired hemoglobin clearance by sinusoidal endothelium promotes vaso-occlusion and liver injury in sickle cell disease.

Kaminski T, Katoch O, Li Z, Hanway C, Dubey R, Alagbe A Haematologica. 2023; 109(5):1535-1550.

PMID: 37941440 PMC: 11063870. DOI: 10.3324/haematol.2023.283792.


Predictors of Mortality in Adults With Sickle Cell Disease Admitted to the Intensive Care Unit in King Saud Medical City, Saudi Arabia.

Alhaj Zeen M, Mohamed N, Mady A, Alamri M, AlShammari S, Alshebaily A Cureus. 2023; 15(5):e38817.

PMID: 37303370 PMC: 10251455. DOI: 10.7759/cureus.38817.


Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial.

Forsyth S, Schroeder P, Geib J, Vrishabhendra L, Konstantinidis D, LaSalvia K Clin Pharmacol Drug Dev. 2022; 11(5):654-665.

PMID: 35019238 PMC: 9306898. DOI: 10.1002/cpdd.1058.


The Role of RBC Oxidative Stress in Sickle Cell Disease: From the Molecular Basis to Pathologic Implications.

Wang Q, Zennadi R Antioxidants (Basel). 2021; 10(10).

PMID: 34679742 PMC: 8533084. DOI: 10.3390/antiox10101608.


Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events.

Jang T, Poplawska M, Cimpeanu E, Mo G, Dutta D, Lim S J Transl Med. 2021; 19(1):397.

PMID: 34544432 PMC: 8454100. DOI: 10.1186/s12967-021-03074-z.